EMERYVILLE, Calif., Aug. 3, 2022
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic
biotechnology company accelerating the world's transition to
sustainable consumption through its Lab-to-Market™ technology
platform, today announced that management will participate in a
fireside chat at the UBS Genomics 2.0 and MedTech Innovations
Summit on Wednesday, August 10, 2022,
at 3:00 pm PT/ 6:00 pm ET in Dana
Point, CA. Speaking on behalf of Amyris will be Sunil Chandran, Chief Science Officer and Head
of Research and Development.
A live webcast of the presentation and a replay will be
available on the Investor Relations section of the company's
website at
https://investors.amyris.com/events-and-presentations.
About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology
company, transitioning the Clean Health & Beauty and Flavors
& Fragrances markets to sustainable ingredients through
fermentation and the company's proprietary Lab-to-Market™
technology platform. This Amyris platform leverages
state-of-the-art machine learning, robotics and artificial
intelligence, enabling the company to rapidly bring new innovation
to market at commercial scale. Amyris ingredients are included in
over 20,000 products from the world's top brands, reaching more
than 300 million consumers. Amyris also owns and operates a family
of consumer brands that is constantly evolving to meet the growing
demand for sustainable, effective and accessible products. For more
information, please visit http://www.amyris.com.
Amyris, the Amyris logo, and Lab-to-Market are trademarks or
registered trademarks of Amyris, Inc. or its subsidiaries in the
U.S. and/or other countries.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-to-participate-at-the-ubs-genomics-2-0-and-medtech-innovations-summit-301598450.html
SOURCE Amyris, Inc.